^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Wnt signalling pathway inhibitor

    Related drugs:
    Apply
    A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor (E7386-J081-102) (NCT04008797)
    Phase 1/2
    Eisai Inc.
    Recruiting
    Last update posted :
    02/11/2025
    Initiation :
    07/11/2019
    Primary completion :
    11/30/2026
    Completion :
    11/30/2026
    EGFR • KRAS • BRAF • MSI
    |
    BRAF V600E • MSI-H/dMMR • BRAF V600 • KRAS wild-type • NRAS wild-type
    |
    paclitaxel • Lenvima (lenvatinib) • doxorubicin hydrochloride • E7386
    A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors (KEYNOTE-C83) (NCT05091346)
    Phase 1/2
    Eisai Inc.
    Completed
    Last update posted :
    10/24/2024
    Initiation :
    10/27/2021
    Primary completion :
    10/15/2024
    Completion :
    10/15/2024
    BRAF
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib) • E7386
    Study of E7386 in Participants With Selected Advanced Neoplasms (NCT03264664)
    Phase 1
    Eisai Inc.
    Active, not recruiting
    Last update posted :
    06/11/2024
    Initiation :
    07/27/2017
    Primary completion :
    03/31/2026
    Completion :
    03/31/2026
    CTNNB1
    |
    CTNNB1 mutation
    |
    E7386
    A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands (NCT01351103)
    Phase 1
    Novartis Pharmaceuticals
    Active, not recruiting
    Last update posted :
    05/30/2024
    Initiation :
    12/01/2011
    Primary completion :
    06/14/2021
    Completion :
    06/18/2024
    BRAF • RNF43
    |
    BRAF mutation • RNF43 mutation
    |
    spartalizumab (PDR001) • WNT974
    Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors (PEPN2011) (NCT04851119)
    Phase 1/2
    Children's Oncology Group
    Recruiting
    Last update posted :
    04/22/2024
    Initiation :
    11/08/2021
    Primary completion :
    06/30/2028
    Completion :
    06/30/2028
    RNF43 • CTNNB1 • TCF7L2
    |
    APC mutation • CTNNB1 mutation • RNF43 mutation • CTNNB1 S45P
    |
    tegavivint (BC2059)
    A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC) (NCT03833700)
    Phase 1
    Eisai Co., Ltd.
    Active, not recruiting
    Last update posted :
    03/06/2024
    Initiation :
    03/05/2019
    Primary completion :
    03/31/2025
    Completion :
    03/31/2025
    RNF43 • APC • AXIN1 • ZNRF3
    |
    APC mutation • CTNNB1 mutation • RNF43 mutation
    |
    E7386
    A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma (NCT05797805)
    Phase 1/2
    Iterion Therapeutics
    Recruiting
    Last update posted :
    02/21/2024
    Initiation :
    09/13/2023
    Primary completion :
    05/01/2026
    Completion :
    06/01/2026
    AXIN1
    |
    CTNNB1 mutation
    |
    Keytruda (pembrolizumab) • tegavivint (BC2059)
    Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma (NCT05755087)
    Phase 1
    Lapo Alinari
    Recruiting
    Last update posted :
    12/29/2023
    Initiation :
    03/06/2023
    Primary completion :
    03/05/2027
    Completion :
    03/05/2027
    MYC • BCL2 • BCL6
    |
    BCL2 expression • MYC expression • MYC translocation • MYC translocation + BCL2 translocation • BCL2 translocation
    |
    tegavivint (BC2059)
    Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer (NCT04780568)
    Phase 1
    Ohio State University Comprehensive Cancer Center
    Recruiting
    Last update posted :
    12/11/2023
    Initiation :
    01/18/2022
    Primary completion :
    12/31/2024
    Completion :
    12/31/2024
    EGFR • NOTCH3
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I
    |
    Tagrisso (osimertinib) • tegavivint (BC2059)
    CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596) (NCT02675946)
    Phase 1b
    Curegenix Inc.
    Recruiting
    Last update posted :
    01/26/2022
    Initiation :
    02/01/2016
    Primary completion :
    03/01/2023
    Completion :
    03/01/2023
    BRAF • RNF43 • CTNNB1 • AXIN1 • RSPO2 • RSPO3
    |
    BRAF V600E • BRAF V600
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • Braftovi (encorafenib) • CGX1321
    A Study of Vantictumab (OMP-18R5) in Combination With Paclitaxel in Locally Recurrent or Metastatic Breast Cancer (NCT01973309)
    Phase 1b
    OncoMed Pharmaceuticals, Inc.
    Completed
    Last update posted :
    09/09/2020
    Initiation :
    09/01/2013
    Primary completion :
    06/01/2017
    Completion :
    12/01/2017
    HER-2
    |
    HER-2 overexpression
    |
    paclitaxel • vantictumab (OMP-18R5)
    Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations (NCT02278133)
    Phase 1/2
    Array BioPharma
    Completed
    Last update posted :
    10/09/2017
    Initiation :
    12/01/2014
    Primary completion :
    05/31/2016
    Completion :
    06/23/2017
    KRAS • RNF43
    |
    KRAS mutation • BRAF V600 • KRAS wild-type • RAS wild-type • RNF43 mutation
    |
    Erbitux (cetuximab) • Braftovi (encorafenib) • WNT974
    Safety and Efficacy Study of PRI-724 Plus Gemcitabine in Subjects With Advanced or Metastatic Pancreatic Adenocarcinoma (NCT01764477)
    Phase 1
    Prism Pharma Co., Ltd.
    Completed
    Last update posted :
    08/17/2017
    Initiation :
    04/01/2013
    Primary completion :
    10/01/2015
    Completion :
    10/01/2015
    BIRC5 • MMP7
    |
    BIRC5 expression
    |
    gemcitabine • 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium • foscenvivint (PRI724)
    Safety and Efficacy Study of PRI-724 in Subjects With Advanced Myeloid Malignancies (NCT01606579)
    Phase 1/2
    Prism Pharma Co., Ltd.
    Completed
    Last update posted :
    08/17/2017
    Initiation :
    07/01/2012
    Primary completion :
    12/30/2016
    Completion :
    12/30/2016
    ABL1 • BCR
    |
    cytarabine • foscenvivint (PRI724)
    Combination Chemotherapy and Bevacizumab With or Without PRI-724 in Treating Patients With Newly Diagnosed Metastatic Colorectal Cancer (PRIMIER) (NCT02413853)
    Phase 2
    University of Southern California
    Withdrawn
    Last update posted :
    04/17/2017
    Initiation :
    11/01/2015
    Primary completion :
    11/01/2017
    Completion :
    11/01/2018
    BRAF • BIRC5
    |
    BIRC5 expression
    |
    Avastin (bevacizumab) • 5-fluorouracil • oxaliplatin • leucovorin calcium • foscenvivint (PRI724)